苏州晟济药业

Shengji Pharma is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the development of long-acting protein and peptide therapeutics. The company leverages its proprietary technology platforms to create improved versions of established biologics, focusing on therapeutic areas such as reproductive health, endocrinology, and metabolic disorders. Its lead candidate, SJ02, is a long-acting follicle-stimulating hormone (FSH) currently in Phase 3 clinical trials for the treatment of infertility. Other pipeline programs include long-acting treatments for growth hormone deficiency and osteoporosis. Shengji Pharma aims to improve patient compliance and therapeutic outcomes through reduced dosing frequency.